|
SECISBP2L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.8140999974724E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.08689999997769E-06 |
| Normal-vs-Stage2 |
7.829000E-04 |
| Normal-vs-Stage3 |
1.46000000977864E-09 |
| Normal-vs-Stage4 |
2.30730001771207E-09 |
| Stage1-vs-Stage2 |
7.366000E-01 |
| Stage1-vs-Stage3 |
4.452200E-02 |
| Stage1-vs-Stage4 |
1.157720E-02 |
| Stage2-vs-Stage3 |
8.535700E-02 |
| Stage2-vs-Stage4 |
4.276200E-02 |
| Stage3-vs-Stage4 |
5.602000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.32070000053086E-07 |
| Normal-vs-AfricanAmerican |
1.193770E-02 |
| Normal-vs-Asian |
2.60929999829074E-08 |
| Caucasian-vs-AfricanAmerican |
3.899000E-01 |
| Caucasian-vs-Asian |
1.345620E-01 |
| AfricanAmerican-vs-Asian |
1.022210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.56620000000474E-05 |
| Normal-vs-Female |
1.26840005165718E-09 |
| Male-vs-Female |
4.467200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.5106000000027E-05 |
| Normal-vs-Age(41-60Yrs) |
2.10160000513326E-09 |
| Normal-vs-Age(61-80Yrs) |
6.32209999906763E-08 |
| Normal-vs-Age(81-100Yrs) |
1.497590E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.844100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.397830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.614400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.694800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.619400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.518400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.385700E-04 |
| Classical-VS-Follicular |
8.891600E-01 |
| Classical-VS-Other |
9.176400E-01 |
| Classical-VS-Normal |
7.35680000030214E-07 |
| Tall-VS-Follicular |
1.221690E-02 |
| Tall-VS-Other |
3.323800E-01 |
| Tall-VS-Normal |
5.51789947067505E-10 |
| Follicular-VS-Other |
9.599400E-01 |
| Follicular-VS-Normal |
7.53030000000265E-05 |
| Other-VS-Normal |
4.238500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.2899000190767E-09 |
| Normal-vs-N1 |
5.22330000030102E-07 |
| N0-vs-N1 |
4.730800E-01 |
|
|
